Zellweger spectrum disorder, the group that contains Zellweger syndrome, is rare: best-available estimates place it at roughly 1 in 50,000 to 1 in 100,000 live births in the United States and comparable populations. True Zellweger syndrome—the severe neonatal end of that spectrum—is rarer still, and recorded counts almost certainly understate how often it occurs. The gap between estimated and detected cases is the core reason this condition is described as underdiagnosed.
The Peroxisome Assembly Failure
Zellweger syndrome is the most severe form of Zellweger spectrum disorder (ZSD), a family of inherited conditions caused by failure of peroxisome biogenesis. Peroxisomes are small organelles that perform oxidation reactions and lipid synthesis. In ZSD, they are built but cannot import the enzymes they need, so they are functionally empty. The result is a cell that cannot run peroxisomal chemistry despite having peroxisomal structures.
The genetics explain the inheritance pattern and much of the variability. Most ZSD cases are autosomal recessive, caused by biallelic pathogenic variants in one of at least 13 PEX genes; PEX1 is the most commonly involved, and two variants (c.2528G>A and c.2097dupT) account for a large share of alleles in affected individuals. A smaller subset involves PEX7 and follows a different inheritance route. Because carriers are unaffected, the variant can pass silently through many generations. That silence is the first mechanism behind underdiagnosis.
The biochemistry explains why the severe form presents so early. Peroxisomes import and run enzymes for very-long-chain fatty acid breakdown, plasmalogen synthesis, bile acid formation, and pipecolic acid oxidation. When import fails, very-long-chain fatty acids accumulate, plasmalogens fall, and bile acids build up. These are not subtle disturbances. They affect the developing brain, liver, and skeleton before birth and in the first weeks of life. A newborn with Zellweger syndrome is not mildly unwell; the biochemical failure is systemic.
The distinction within the spectrum matters for counting. ZSD spans a continuum from severe Zellweger syndrome through infantile Refsum disease to milder adult-onset phenotypes. The severe end is what most clinicians mean by Zellweger syndrome specifically. Milder forms may be recognized decades later or never formally labeled, which means any single number conflates distinct diagnostic categories. Plainly: the name covers a range, and the range is part of why counts are fuzzy.
Quantifying a Rare Disorder
The most defensible figure is a birth prevalence for the whole spectrum of roughly 1 in 50,000 to 1 in 100,000. The severe Zellweger syndrome phenotype sits at the low end of that detection frequency, though published breakdowns by subtype are inconsistent across registries. That inconsistency itself is a finding: different surveillance systems define and count the disorder differently.
| Population / Setting | Reported Frequency | What It Reflects |
|---|---|---|
| General US births (spectrum) | ~1 in 50,000–100,000 | Clinical and biochemical detection, not genetic truth |
| Severe Zellweger phenotype | Rarest end of that range | Early lethality limits diagnosis |
| Carrier frequency (PEX1 variants) | Higher than affected births | Recessive inheritance masks carriers |
| Newborn screening pilots (expanded) | Higher detection than clinical series | Ascertainment bias toward broader phenotypes |
| Autopsy/sudden-death series | Occasional unexpected cases | Death before diagnosis |
The pattern across rows is consistent: every method that looks harder finds more. Clinical series count children who reach a specialist. Screening pilots count biochemical abnormalities before symptoms declare themselves. That direction of error—under-counting—is the key to the underdiagnosis claim.
Incidence versus prevalence deserves a note. Because the severe form is often lethal in infancy, incidence (new cases per year) and prevalence (living cases at a point in time) diverge sharply. A high incidence with low prevalence is exactly what a rapidly fatal, often undiagnosed condition looks like. Comparing prevalence figures across studies without accounting for this will produce false reassurance.
Why the Numbers Hide Cases
Underdiagnosis is not a single failure. It is the sum of several mechanisms that each remove a case from the count.
First, lethality precedes diagnosis. Severe Zellweger syndrome often presents with hypotonia, seizures, feeding difficulty, and liver dysfunction in the neonatal period. Infants may die before a metabolic workup is completed. A death attributed to respiratory failure or sepsis may never be counted as a peroxisomal disorder. The diagnostic window closes faster than the testing process opens.
Second, the milder spectrum evades recognition. Infantile Refsum disease and milder ZSD can present with hearing loss, vision problems, developmental delay, and ataxia that overlap with far more common conditions. Without targeted biochemical testing, these cases are attributed to cerebral palsy, sensorineural hearing loss, or nonspecific developmental delay.
Third, phenotype overlap creates diagnostic substitution. The very-long-chain fatty acid elevation and plasmalogen deficiency seen in ZSD resemble findings in other peroxisomal and metabolic disorders. A clinician who suspects a metabolic disease but orders a narrow panel may stop at the first abnormal result, closing the case under another label.
Fourth, access and awareness are uneven. Specialized biochemical testing for very-long-chain fatty acids and plasmalogens is not universally available. Where it is available, it must be ordered, and ordering requires the clinician to consider the diagnosis. That consideration is less likely when the condition is described in textbooks as vanishingly rare.
The counterintuitive detail is this: carrier frequency does not feel rare. PEX1 pathogenic variants are common enough in populations that carrier screening panels sometimes include them, even though affected births are unusual. A disorder can be genetically common and clinically invisible at the same time. Underdiagnosis is the space between those two facts.
Reconciling Thresholds and Labels
Different sources give different numbers for the same underlying biology, and the differences are informative rather than contradictory.
Clinical series report lower frequencies because they count diagnosed patients only. Screening pilots report higher frequencies because they detect biochemical abnormalities, including mild and variant cases that clinical care never flags. Registry estimates fall in between because they depend on voluntary reporting. Subtype-specific figures for severe Zellweger syndrome are usually lower than spectrum-wide figures, sometimes by an order of magnitude.
The reconciliation is direct: these are not competing measurements of one quantity. They are measurements of detection at different sensitivities. A lower number from a clinical series is not more accurate; it is a count of cases that reached clinical attention. The spectrum-wide estimate is the better central figure, and the severe phenotype's true frequency likely sits above the lowest reported values.
A practical consequence follows. When a clinician asks how common Zellweger syndrome is, the honest answer has two parts: roughly 1 in 50,000 to 1 in 100,000 births for the spectrum, and probably undercounted for the severe end. Quoting the lowest number without that caveat misrepresents the state of knowledge.
Misconceptions That Delay Recognition
Several persistent beliefs keep the diagnosis low on differential lists.
Belief: It is too rare to test for. Reality: rare conditions still present to clinicians, and targeted tests exist precisely because the presentation is recognizable once considered. Belief: A normal newborn exam excludes it. Reality: some findings emerge over days to weeks, and lethal cases may not be captured in routine newborn exams. Belief: Only neurologists should suspect it. Reality: hepatologists, ophthalmologists, and audiologists see overlapping findings first. Belief: A single abnormal test confirms it. Reality: confirmation requires coordinated biochemical and genetic evidence; single tests have false positives and ambiguous results. Belief: Milder forms are a different disease. Reality: they are the same spectrum and often present to adult clinics.
The professional caveat is that prevalence estimates for ultra-rare disorders are inherently unstable. Small changes in case definition or testing criteria can move the number substantially. Reporting a point estimate without acknowledging that instability is a form of false precision. The responsible framing is a range with a mechanistic explanation for why the range exists.
Practical Actions and Thresholds
There is no population-wide prevention step, but there are concrete decision points that improve detection. These are clinical and public-health actions, not patient-specific instructions.
Suspect and refer early: an infant with unexplained hypotonia, seizures, feeding difficulty, and liver dysfunction should prompt metabolic evaluation before discharge rather than after outpatient follow-up. Order the right test: very-long-chain fatty acid analysis combined with plasmalogen measurement, followed by genetic testing, is the standard biochemical-genetic pathway; a single test is not sufficient for a severe phenotype. Use newborn screening logic where pilots exist: expanded screening detects biochemical abnormalities earlier, and pilot results consistently exceed clinical detection rates. Flag the overlap syndromes: hearing loss plus vision loss plus developmental delay in an infant should raise the peroxisomal question before an isolated diagnosis is assigned. Track deaths carefully: unexpected neonatal death with metabolic or liver findings warrants post-mortem biochemical investigation where consent permits.
A practical threshold for suspicion: when two or more organ systems (neurologic, hepatic, ophthalmologic, skeletal) are affected in an infant, the pretest probability of a peroxisomal disorder is no longer negligible, regardless of the population prevalence. That is a reasoning threshold, not a diagnostic criterion. Any actual diagnosis requires confirmatory biochemical and genetic testing by a qualified clinician.
The funding and access threshold matters too. Where specialized testing is unavailable or unaffordable, underdiagnosis becomes structural rather than clinical. Surveillance systems that rely only on voluntary reporting will continue to miss cases that never reach a reporting site. No single number resolves this; better ascertainment does.
Limits of the Evidence
What can be concluded is narrower than it first appears. The spectrum-wide prevalence range of roughly 1 in 50,000 to 1 in 100,000 is the best-supported figure, and the severe Zellweger phenotype is rarer within that range. What cannot be reliably concluded is a precise subtype prevalence, a stable incidence trend, or a definitive carrier-based prediction of affected births. Registries vary in completeness, screening pilots are not uniformly implemented, and case definitions differ across jurisdictions.
Two limitations deserve emphasis. First, the direction of bias is known—toward undercounting—but its magnitude is not. The gap between estimated and true frequency is plausible and mechanistic, not measured. Second, the milder end of the spectrum blurs the boundary between disorder and normal variation, which makes any single prevalence number sensitive to how the boundary is drawn. Plainly: the biology is stable, the counting is not.
The most defensible takeaway is that Zellweger syndrome is genuinely rare and genuinely underdiagnosed, and that both statements are true for reasons that can be explained. Genetic rarity and diagnostic invisibility are different phenomena, and conflating them is where thin explanations go wrong. This one tries to keep them separate and to state plainly which numbers are measured and which are inferred.
One more professional caveat: this article describes mechanisms and published estimates, not patient-specific guidance. Suspected cases belong with metabolic specialists, and confirmatory testing is a clinical decision. The science explains why detection matters; the clinician decides how to look.
Sources
Eunice Kennedy Shriver NICHD, Zellweger spectrum disorder overview (National Institutes of Health). National Organization for Rare Disorders, Zellweger spectrum disorder summary. GeneReviews, Zellweger spectrum disorders (PEX gene–related). American College of Medical Genetics and Genomics, carrier screening resources.